Tivic Health Systems Beheer

Beheer criteriumcontroles 4/4

De CEO Tivic Health Systems is Jennifer Ernst, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 329.34K, bestaande uit 83.5% salaris en 16.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde $ 3.10K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.7 jaar en 5.3 jaar.

Belangrijke informatie

Jennifer Ernst

Algemeen directeur

US$329.3k

Totale compensatie

Percentage CEO-salaris	83.5%
Dienstverband CEO	8.2yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	5.7yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

Analyse CEO-vergoeding

Hoe is Jennifer Ernst's beloning veranderd ten opzichte van Tivic Health Systems's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$329k	US$275k	-US$8m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$419k	US$275k	-US$10m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$249k	US$218k	-US$8m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$197k	US$181k	-US$4m
Dec 31 2019	US$226k	US$210k	-US$4m

Compensatie versus markt: De totale vergoeding ($USD 329.34K ) Jennifer } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Jennifer is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jennifer Ernst (56 yo)

8.2yrs

Tenure

US$329,340

Compensatie

Ms. Jennifer Ernst is a Co-Founder, CEO and Director of Tivic Health Systems, Inc. since September 2016 and was its Chief Financial Officer from September 2016 to July 2021. Ms. Ernst served as Chief Strat...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jennifer Ernst	Co-Founder	8.2yrs	US$329.34k	0.15% $ 3.1k
Blake Gurfein	Chief Scientific Officer	5.7yrs	US$405.02k	0.015% $ 308.7
Lisa Wolf	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens

5.7yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TIVC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jennifer Ernst	Co-Founder	8.2yrs	US$329.34k	0.15% $ 3.1k
Sheryle Bolton	Independent Chair of the Board	5.3yrs	US$65.12k	0% $ 0
Christina Valauri	Director	less than a year	geen gegevens	geen gegevens
Dean Zikria	Independent Director	5.3yrs	US$37.12k	0% $ 0

5.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TIVC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Tivic Health Systems Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd